Drugs / PM012
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01715350 | May 2012 → Sep 2014 | Alzheimer disease | VTBIO Co. LTD | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05811000 | Nov 2020 → Feb 2021 | Alzheimer disease | Mediforum Ltd., Co. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PM012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05811000 ↗ |
| Route | Oral | “650mg/1 tablet, PO, 12weeks” NCT01715350 ↗ |